US Stock MarketDetailed Quotes

BTAI BioXcel Therapeutics

Watchlist
  • 2.310
  • -0.070-2.94%
Close Feb 14 16:00 ET
  • 2.440
  • +0.130+5.63%
Post 19:56 ET
7.17MMarket Cap-0.07P/E (TTM)

About BioXcel Therapeutics Company

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Company Profile

SymbolBTAI
Company NameBioXcel Therapeutics
Listing DateMar 8, 2018
Issue Price11.00
Founded2017
CEODr. Vimal Mehta, PhD
MarketNASDAQ
Employees74
Fiscal Year Ends12-31
Address555 Long Wharf Drive,12th floor
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06511
Phone1-475-238-6837

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Vimal Mehta, PhD
  • Director, Chief Executive Officer and President
  • 4.73M
  • Dr. Frank D. Yocca, PhD
  • Senior Vice President and Chief Scientific Officer
  • --
  • Richard I. Steinhart
  • Senior Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Javier Rodriguez
  • Senior Vice President, Chief Legal Officer and Corporate Secretary
  • 1.12M
  • Dr. Vincent J. O'Neill, M.D.
  • Executive Vice President, Chief of Product Development and Chief Medical Officer
  • --
  • Dr. Peter Mueller,PhD
  • Chairman of the Board
  • 367.33K
  • Dr. Rajiv Patni, M.D.
  • Director
  • --
  • David J. Mack
  • Independent Director
  • --
  • Michael Miller
  • Independent Director
  • 332.33K
  • June Bray
  • Independent Director
  • 327.33K
  • Dr. Sandeep Laumas, M.D.
  • Independent Director
  • 329.83K
  • Dr. Michal Votruba, M.D.,PhD
  • Independent Director
  • 307.33K

Trending Stocks

Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More